Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital and Key Laboratory of Cancer Prevention and Therapy, TianJin, China.
Eur Rev Med Pharmacol Sci. 2013 Mar;17(6):752-7.
The aim of this study was to clarify the clinico-pathological outcome and prognostic significance of phospholipase A2 group IIA (PLA2G2A) in esophageal squamous cell carcinoma (ESCC).
Immunohistochemical staining for PLA2G2A was performed on surgical specimens obtained from 132 patients with ESCC, and 43 from matched adjacent non-malignant sites. Differences in PLA2G2A expression and clinical characteristics were compared by χ2 test. Correlations between prognostic outcomes and with PLA2G2A expression were investigated using Kaplan-Meier analysis and the Cox proportional hazards model.
Immunoreactivity of PLA2G2A was observed in 32% (42 of 132) of ESCC tissues compared with negative staining in matched adjacent non-malignant sites. In addition, PLA2G2A expression inversely correlated with pathological classification (p < 0.05 for T, N, and M classifications) and clinical staging (p = 0.03). Furthermore, patients with positive PLA2G2A had prolonged overall survival (p < 0.01).
Reduced PLA2G2A expression may be a risk factor for advanced clinicopathological classification and poor patient survival. These findings suggest that PLA2G2A may serve as a useful marker for the prognostic evaluation of ESCC patients.
本研究旨在阐明磷脂酶 A2 组 IIA（PLA2G2A）在食管鳞状细胞癌（ESCC）中的临床病理结局和预后意义。
对 132 例 ESCC 手术标本和 43 例配对的非恶性相邻组织进行 PLA2G2A 免疫组织化学染色。通过卡方检验比较 PLA2G2A 表达差异和临床特征。采用 Kaplan-Meier 分析和 Cox 比例风险模型探讨预后结果与 PLA2G2A 表达的相关性。
与配对的非恶性相邻组织相比，ESCC 组织中 PLA2G2A 的免疫反应性为 32%（42/132），呈阴性染色。此外，PLA2G2A 的表达与病理分级（T、N 和 M 分类，p<0.05）和临床分期（p=0.03）呈负相关。此外，PLA2G2A 阳性患者的总生存期延长（p<0.01）。
PLA2G2A 表达降低可能是高级临床病理分类和患者生存不良的危险因素。这些发现提示 PLA2G2A 可能成为 ESCC 患者预后评估的有用标志物。
